Impact of an Inpatient Allergy Guideline on β-Lactam and Alternative Antibiotic Use

J Allergy Clin Immunol Pract. 2023 Aug;11(8):2557-2567.e6. doi: 10.1016/j.jaip.2023.04.051. Epub 2023 May 12.

Abstract

Background: A guideline identifying when inpatients with penicillin or cephalosporin antibiotic allergy labels (PCAAL) can receive β-lactam antibiotics increased β-lactam receipt at a large northeastern US health care system.

Objective: To report outcomes of implementing a similar guideline and electronic order set (OS) at an independent academic health care system.

Methods: Penicillin/cephalosporin receipt (percentage of inpatients receiving full doses) and alternative antibiotic use (days of therapy per 1000 patient-days [DOT/1000PD]) were compared over 3 periods before (February 1, 2017, to January 31, 2018) and after guideline implementation (February 1, 2018, to January 31, 2019), and after OS implementation (February 1, 2019, to January 31, 2020) among inpatients with PCAAL admitted on medical services with access to guideline/OS and education (Medical-PCAAL, n = 8721), surgical services with access to guideline/OS without education (Surgical-PCAAL, n = 5069), and obstetrics/gynecology services without interventions (Ob/Gyn-PCAAL, n = 798) and inpatients without PCAAL admitted on the same services (Medical-No-PCAAL, n = 50,840; Surgical-No-PCAAL, n = 29,845; Ob/Gyn-No-PCAAL, n = 6109). χ2 tests were used to compare categorical variables, and analysis of variance was used to compare continuous and interrupted time series analyses (ITSA) to investigate the guideline/OS implementation effect on penicillin/cephalosporin receipt.

Results: In the Medical-PCAAL group, penicillin/cephalosporin receipt increased (58%-68%, P < .001), specifically for cefazolin (8%-11%, P = .02) and third- to fifth-generation cephalosporins (43%-48%, P = .04), and aztreonam use decreased (12 DOT/1000PD, P = .03). In the Medical-No-PCAAL group, penicillin/cephalosporin receipt increased (88%-90%, P = .004), specifically for penicillin (40%-44%, P < .001), without changes in aztreonam use. Significant changes were not observed in these outcomes on surgical or obstetrics/gynecology services. Per ITSA, guideline/OS implementation was associated with increased penicillin/cephalosporin receipt in the Medical-PCAAL group only.

Conclusion: Guideline and OS implementation was associated with improved antibiotic stewardship on inpatient services that also received allergy education.

Keywords: Antibiotic allergy; Antibiotic stewardship; Aztreonam; Cephalosporin allergy; Graded challenge; Guideline; PCN allergy; Quality improvement; Stewardship; β-Lactam allergy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Aztreonam
  • Cephalosporins / adverse effects
  • Cephalosporins / therapeutic use
  • Drug Hypersensitivity* / drug therapy
  • Humans
  • Hypersensitivity* / drug therapy
  • Inpatients
  • Penicillins / adverse effects
  • Retrospective Studies
  • beta-Lactams / adverse effects

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Aztreonam
  • Penicillins
  • Cephalosporins